Pure Global
NCT04202952

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects

A Phase Ib/IIa, Single Center, Randomized, Open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability， Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
Sunshine Lake Pharma Co., Ltd.·Phase 1/2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
HEC110114 Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sunshine Lake Pharma Co., Ltd.
Location
Jilin, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Jul 06, 2020
End date
Aug 27, 2020
Enrollment
24 participants
Primary outcome

Adverse Events

Summary

A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending
 Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114
 Tablets in HCV-infected Subjects

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04202952
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04202952 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.